Arrowhead to Participate in Panel Discussions at 16th Annual BIO CEO & Investor Conference

PASADENA, Calif. — February 4, 2014 — Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that members of management will be panelists on two panel discussions at the 16^th Annual BIO CEO & Investor Conference on Monday, February 10, 2014.  President and CEO, Christopher Anzalone, Ph.D., and COO and head of R&D, Bruce Given, M.D., will participate in discussions at 9:00 am EST titled, “Solution Development: Aiming the Whole Pipeline at a Single Goal,” and at 10:30am EST titled, “Delivering the [RNAi] Goods,” respectively.

Now in its sixteenth year, the BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded and select private biotech companies.  The conference is being held February 10-11 at the Waldorf Astoria in New York City.

About Arrowhead Research Corporation

Arrowhead Research Corporation is a biopharmaceutical company developing targeted RNAi therapeutics. The company is leveraging its proprietary drug delivery technologies to develop targeted drugs based on the RNA interference mechanism that efficiently silence disease-causing genes. Arrowhead technologies also enable partners to create peptide-drug conjugates that specifically home to cell types of interest while sparing off-target tissues. Arrowhead’s pipeline includes clinical programs in chronic hepatitis B virus and partner-based programs in obesity and oncology.

For more information please visit http://www.arrowheadresearch.com, or follow us on Twitter @ArrowRes. To be added to the Company’s email list to receive news directly, please send an email to ir@arrowres.com